Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So you sold and you want it to go lower, or you are currently shorting it, never the less, you want it to go lower.
There is no reason this stock should be under $5.00 right now.
New job hire, so they do work weekends, to meet production demands
http://vcel.com/careers/?req=634572
Working Conditions and Physical Demands:
•May be required to work in classified and controlled areas such as clean room environment wearing special garments. Additionally, personal protective equipment must be worn due to safety requirements.
•May be required to stand for long periods of time while performing physical duties.
•Must be able to lift, carry, push and pull up to 40 lbs.
•Able to work a flexible schedule including weekends and/or holidays as required to meet production demands.
VCEL
lasers
http://in.reuters.com/article/us-china-pharmaceuticals/china-to-accept-overseas-trial-data-in-bid-to-speed-up-drug-approvals-idINKBN1CE080?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29
Where did you find ICT being a billion dollar company ?
ICT is a Multi $Bil Pharma and China's largest stem cell Biotech
I didn't know that, that is AWESOME info, so ICT is Big Pharma
$10 Mil to finish off ph3 is chump change, I hope we longs get a deal favorable to us. and USA
I see where you are going with this. VERY NICE
So can we get a multi partnership deal with two BP's, lets say ICT we have, and another at the same time?
We are not General Motors or Ford, we cannot service the entire world. So this is making a bit of sense.
*******************
However Vericel is most definitely advanced with their autologous stemcells from bone marrow.
Like in top 10 and 3 or 4 years forward advanced
VCEL
I am picking up what you are laying down
Then why on Earth did Nick go to Meeting on the Mesa ?
You bring up some very interesting talking points.
Is ICT a fortune 500 company equivalent? Just who are they.
Wouldn't Takeda be a better partner candidate.
Wonder if they will take private investor calls on the next CC?
Congrats on the picture posting capabilities, think this is the first time I seen you post a pic, NICE JOB !!!
Unless you been holding back. LOL
At any rate, Maybe Nick will give us an update as to what is up.
I will take some nice News on partnership this week forward.
Doesn't it seem like the website of ICT is mirrored to copy VCEL, why would they have Americans on a Chinese website, just wondering?
When I click over to Chinese language, it is still Americans.
+++++++++
From the 2nd Quarter CC, this is all they say.
Turning to other important business developments, during the second quarter we announced that the company had entered into a license agreement with Innovative Cellular Therapeutics or ICT for the development and distribution of our product portfolio in the territory of Greater China, South Korea, Singapore and select other countries in South East Asia.
China is the second largest healthcare market in the world and ICT is the leading cell therapy company with a portfolio of Carticel therapies for the treatment of cancer. We’re very pleased to have entered in the strategic collaboration which allows us to begin to develop a global footprint for our product portfolio and to create another potential revenue stream for the company.
No ICT updates at Ladenburg, or the Meeting On The Mesa.
And come to think of it, I don't recall any ICT updates
at the 2nd Quarter CC/ER
Well thought out post. Thought we already have an open line of credit at a bank for like $20M
At any rate, the last pr clearly stated only a partner will fund ph3 Ixcell
I do hope Takeda is our partnership for USA and Japan.
Well, then, from now to next ER/CC, it's going to be a wild ride.
We still show up on ICT website homepage.
The Chinese are very rich, they have all our money.
Yes lasers, we know about that from the press release, had he got the initial 6 million already, we would have seen an 8-K on that. Nick has been hush hush quiet in the last 3 months. Just like the BTIG recent article stated, too.
They still need an 8-k on Thursdays press release, don't they?
When VCEL starts doing 1000 maci's a quarter, they will have enough money in the bank to do their own funding of PH3
That would be non-dilutive
We might just be doing a 1000 maci's in the 4th Quarter anyways, and by then the crossover 2b study will be complete in Feb 2018
Nothing other than the Chinese are known for stealing technology.
How do you sue them if they screw you over? You can't.
Guess we will have to just see where the chips roll.
I entertain the idea, but not ICT. As long as the partnership doesn't overtake in %'s more than they would deserve.
The ceo has been saying for more than a year that IXCELL will go to commercialization in a non - diluted manner. So here we are.
Unless Nick has the FDA layout the criteria for PH3 and Nick holds back Until VCEL has the money in the bank to do it themselves.
What our your ideas?
****************
VCEL clearly stated in the last press release
Consistent with its previously disclosed strategy to focus investments on its high-growth commercial business, the Company does not plan to conduct any additional clinical studies for ixmyelocel-T unless fully funded by a partner.
pbor, I don't understand what you are trying to say, in bold
Can you further explain what you mean?
VCEL Now this is cool, the tutes held this up and are accumulating
https://www.smarteranalyst.com/2017/10/05/btig-buyers-vericel/
VCEL is still over 5 bucks and RSI is reset to 55
If anything, this is building a stronger/higher shareholder base.
FDA to me gave IXCELL a thumbs up, just do another trial., so, get a partner, and we fly
Would that crossover study qualify that the results are to be finished by Feb 2018, qualify for what the FDA is asking for?
That is his knack, he has the brains, and the gift of gab, so I
am very confident he will pilot the VCEL to my destiny, if you don't mind me saying
I joined the Ixcell club many years ago, and now it is in front of the FDA, just small time to wait for the response from them.
They made it clear today there was only 7 RMAT's awarded by the FDA, great moment in time to be one of them.
I was watching his hand movement on the panel conference, he was thinking 100mph
Thoughts crossed my mind of big pharma trying to snag him up, he is brilliant
That was a great panel conference, it demonstrated ceo Nick was very competent, worth his weight in gold.
Thus, VCEL is golden. I am a very happy VCEL LONG.
I think we are still waiting on Anthem, per the 2nd QTR CC
VCEL - Nice - United Healthcare showing MACI coverage
https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medicaid-comm-plan/autologous-chondrocyte-transplantation-knee-cs.pdf
VCEL
GM lasers,
Good chance we pick up 100k in market cap through Wednesday unless
steller news is released tomorrow or Tuesday. Then it speeds up.
This guy is brilliant to hold a position so powerful, so young.
https://www.fda.gov/aboutfda/centersoffices/ucm557569.htm
VCEL
Nice post
This week and weeks coming forward are going to be very interesting as events fold out.
As you stated, the market cap is going to have exponential growth.
I can't wait till Wednesday, the whole world of investors will be monitoring this live webcast, the most important one to date.
VCEL will be with some large company speakers this Wednesday at 9.15am,
IMPLICATIONS OF COMMERCIALIZATION: WHAT DOES APPROVAL MEAN?
http://www.meetingonthemesa.com/agenda/
Speakers:
Bob Azelby, EVP, Chief Commercial Officer, Juno Therapeutics
Nick Colangelo, President and CEO, Vericel Corporation
Pascal Touchon, D.V.M., SVP and Global Head, Cell and Gene, Novartis Oncology
Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
http://www1.salary.com/Robert-Azelby-Salary-Bonus-Stock-Options-for-JUNO-THERAPEUTICS-INC.html
https://www.novartisoncology.com/sites/www.novartisoncology.com/files/Novartis_Bio_Pascal_Touchon.pdf
http://www1.salary.com/Jeffrey-T-Walsh-Salary-Bonus-Stock-Options-for-BLUEBIRD-BIO-INC.html
VCEL
Just made a major discovery, you will be impressed. IN BOLD BELOW
PLENARY SESSION: IMPLICATIONS OF COMMERCIALIZATION: WHAT DOES APPROVAL MEAN? {Ballroom 1}
This is CAR-T cell therapy’s breakthrough year. The first product, Novartis’ Kymriah, is now approved to treat acute lymphoblastic lymphoma, and therapies for other cancers are hot on its heels. This panel will explore the scientific, clinical, policy and business issues surrounding CAR-T approvals, and set the stage for moving these therapies into mainstream medicine.
Chair:
Amy DuRoss, CEO, Vineti
Speakers:
Bob Azelby, EVP, Chief Commercial Officer, Juno Therapeutics
Nick Colangelo, President and CEO, Vericel Corporation
Pascal Touchon, D.V.M., SVP and Global Head, Cell and Gene, Novartis Oncology
Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
https://vineti.com/about/
http://vcel.com/about-vericel/#BoardOfDirectors
Click the links and see if you see someone in common
VCEL
VCEL - BTIG Reiterates Bullish Stance on Vericel Corp (VCEL) Following Investor Meetings with Management
https://www.smarteranalyst.com/2017/09/29/btig-reiterates-bullish-stance-vericel-corp-vcel-following-investor-meetings-management/
Highlights from investor meetings with Vericel management.
--------------------------------------------------------------------------------
Jason Cohen, Editor-September 29, 2017, 3:04 PM EDT
Analyst Ryan Zimmerman of equity research firm BTIG has recently hosted investor meetings with management of Vericel Corp (NASDAQ:VCEL) in San Francisco. CEO Nick Colangelo and CFO Gerard Michel spoke on a variety of topics related to Vericel’s business. Overall, Zimmerman sounds more enthusiastic about his Buy rating following the meeting. (To watch Zimmerman’s track record, click here)
In a research note to clients Zimmerman wrote, “We came away from meetings with additional color on the market opportunity, the company’s commercialization efforts, and Vericel’s regulatory focus for other assets beyond MACI (i.e. Ixmyelocel-T). Investor interest was encouraging and while shares have moved up since the last quarterly earnings call, we continue to see upside as VCEL is growing revenue faster than peers but remains at a discount on a revenue basis.”
“Mgmt. sees the opportunity for MACI among patients as ~10k-15k patients today and these estimates remain conservative, limited for younger patients with favorable commercial insurance. We believe the market may be larger. That said, from a MD standpoint, there were a core group of ~350 users of Carticel previously (although up to 1,000 may send in biopsies), mgmt. sees the potential MD opportunity as ~3,000 who could potentially add MACI to their practice,” the analyst added.
Furthermore, “Investors were interested to hear about Ixmyelocel-T, as a potential catalyst for shares may be near-term. Mgmt. has remained constrained on discussion of the non-core asset so as not to get ahead of themselves but Vericel expects to meet with the FDA before the end of the 3rd quarter.
Shares of Vericel are rising nearly 8% to $6.07 as of 2:59PM EDT.
VCEL
I still think we get major news either Monday morning or Tuesday morning regarding FDA and Ixmyelocel-T
Otherwise, what can ceo Nick talk about at Weds panel live webcast if the accelerated approval isn't already 8-K'd to us first.
There will be no sleeping next week if this 8-K gets edgarized.
I am waiting for Bank of America and others to upgrade, Not sure about Zacks, looked it up a week ago and didn't see anything.
We get FDA accelerated approval and every tute/analyst out there is going to try to make a name for themselves. JMHO
First heart failure treatment for DCM, WTF, a no brainer
Same token, waiting for the BAKER BROTHERS to take position and file one of those 13 F or 13 G
Let me let you know that chick has not aged in years, many years
Running out of free posts, but like you say lasers, interesting start of Oct 2017, this time with tutes on board more then ever.
I hope this panel is to discuss Ixcell, and maybe other RMAT potentials
VCEL CEO panel live Wednesday webcast is 9:15am PDT California time, so mid day here in the Midwest, the 5:45pm live webcast will occur when the market is closed, even AH
3 hour time difference
Guessing the 6.30 will be taken out tonight before closing
Yep, its going to be a nice nestegg if FDA approves, find out in the next few weeks or so
Next week may turn out to be very moving, hoping for news Monday or Tuesday or Wednesday before the panel conference.